Risk of hepatitis B reactivation in hepatitis B surface antigen seronegative and core antibody seropositive kidney transplant recipients

2018 ◽  
Vol 21 (1) ◽  
pp. e13009 ◽  
Author(s):  
Sara Querido ◽  
André Weigert ◽  
Teresa Adragão ◽  
Luís Rodrigues ◽  
Cristina Jorge ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Kidney Transplant ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Hepatitis B Reactivation

Rituximab and hepatitis B reactivation in HBsAg-negative/ anti-HBc-positive kidney transplant recipients

2017 ◽  
Vol 32 (4) ◽  
pp. 722-729 ◽  
Author(s):  
Juhan Lee ◽  
Jun Yong Park ◽  
Kyu Ha Huh ◽  
Beom Seok Kim ◽  
Myoung Soo Kim ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Hepatitis B Reactivation

scholarly journals Outcome after kidney transplantation in hepatitis B surface antigen-positive patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Hyejin Mo ◽  
Sangil Min ◽  
Ahram Han ◽  
In Mok Jung ◽  
Jongwon Ha
Keyword(s):  
Hepatitis B ◽  
Kidney Transplant ◽  
Graft Survival ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Hbv Reactivation ◽  
Kidney Transplant Recipients ◽  
Old Patients ◽  
Significant Difference ◽  
Patient And Graft Survival

AbstractFew reports detail the actual outcome of Hepatitis B Surface Antigen-positive patients after kidney transplant. HBsAg-positive patients who underwent kidney transplant between January, 1999, and December, 2018, were reviewed retrospectively. Outcomes including hepatitis B reactivation rate, risk factors for reactivation, and patient and graft survival rates were analyzed. Seventy-seven patients were enrolled (47.1 ± 11.5 years old). Patients received ABO-incompatible (n = 5), crossmatch positive transplant (n = 2), and re-transplant (n = 4). Forty-six patients received prophylactic; 19, medication at least 3 months before the transplant; and 12, did not receive medication. Seventeen out of 76 patients developed reactivation post-transplant. 52.9% of HBV reactivation was accompanied by hepatitis. Inappropriate, other than lifelong prophylactic, antiviral agents (HR = 7.34, 95% CI 1.51–35.69, P = 0.01) and high hepatitis DNA (≥ 1000 IU/ml) pre-transplant (HR = 4.39, 95% CI 1.08–17.81, P = 0.04) increased reactivation risk. There was no significant difference in patient and graft survival between antigen positive patients who received antiviral agent and propensity score matched negative patients. HBsAg positivity in kidney transplant recipients is associated with substantial HBV reactivation rate. Lifelong antiviral therapy is mandatory, and patients with high preop HBV titer should be monitored closely for HBV reactivation.

scholarly journals POS-768 Hepatitis B reactivation in kidney transplant recipients treated with belatacept

2021 ◽  
Vol 6 (4) ◽  
pp. S335
Author(s):  
C. Schwarz ◽  
A. Morel ◽  
E. Rondeau ◽  
M. Marie ◽  
K. Dahan ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Hepatitis B Reactivation

scholarly journals Rituximab and hepatitis B reactivation in HBsAg-negative/anti-HBc-positive kidney transplant recipients

2017 ◽  
Vol 32 (5) ◽  
pp. 906-906 ◽  
Author(s):  
Juhan Lee ◽  
Jun Yong Park ◽  
Kyu Ha Huh ◽  
Beom Seok Kim ◽  
Myoung Soo Kim ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Hepatitis B Reactivation

scholarly journals Immune Complex Mediated Glomerulonephritis with Acute Thrombotic Microangiopathy following Newly Detected Hepatitis B Virus Infection in a Kidney Transplant Recipient

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Tracey Salter ◽  
Hannah Burton ◽  
Sam Douthwaite ◽  
William Newsholme ◽  
Catherine Horsfield ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Kidney Transplant ◽  
Immune Complex ◽  
Thrombotic Microangiopathy ◽  
Hbv Infection ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Vaccine Escape Mutant ◽  
B Virus

Hepatitis B virus (HBV) presents a risk to patients and staff in renal units. To minimise viral transmission, there are international and UK guidelines recommending HBV immunisation for patients commencing renal replacement therapy (RRT) and HBV surveillance in kidney transplant recipients. We report the case of a 56-year-old male who was immunised against HBV before starting haemodialysis. He received a deceased donor kidney transplant three years later, at which time there was no evidence of HBV infection. After a further six years he developed an acute kidney injury; allograft biopsy revealed an acute thrombotic microangiopathy (TMA) with glomerulitis, peritubular capillaritis, and C4d staining. Due to a “full house” immunoprofile, tests including virological screening were undertaken, which revealed acute HBV infection. Entecavir treatment resulted in an improvement in viral load and kidney function. HBV genotyping demonstrated a vaccine escape mutant, suggesting “past resolved” infection that reactivated with immunosuppression, though posttransplant acquisition cannot be excluded. This is the first reported case of acute HBV infection associated with immune complex mediated glomerulonephritis and TMA. Furthermore, it highlights the importance of HBV surveillance in kidney transplant recipients, which although addressed by UK guidelines is not currently practiced in all UK units.

Entecavir treatment in kidney transplant recipients infected with hepatitis B

2014 ◽  
Vol 28 (9) ◽  
pp. 1010-1015 ◽  
Author(s):  
Desmond Y. H. Yap ◽  
Susan Yung ◽  
Colin S. O. Tang ◽  
Wai Kay Seto ◽  
Maggie K. M. Ma ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients
Sign in / Sign up

Export Citation Format

Share Document